RxDoctor Payments Data

Omid Vahdat, MD

Interventional Cardiology · Los Alamitos, CANPI 1033164330

Payments from drug & device makers

$21,418in general payments, 2019–2025

Across 634 payments — averaging $33.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Edwards Lifesciences$4K
  • Abiomed$1K
  • Novartis$1K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • plus $8K from 36 others

What the payments were for

  • Consulting fees$1,4887%
  • Travel & lodging$4,33320%
  • Food & beverage$15,55073%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,418 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$977,208
Medicare patients
1,465
Services billed
9,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban516$567,844
XareltoRivaroxaban183$185,873
EntrestoSacubitril/Valsartan102$146,285
CamzyosMavacamten14$108,404
JardianceEmpagliflozin58$76,261
FarxigaDapagliflozin Propanediol75$69,602
VascepaIcosapent Ethyl100$59,181
OzempicSemaglutide33$33,640
Praluent PenAlirocumab27$29,650
Repatha SureclickEvolocumab42$26,757
Icosapent Ethyl59$16,848
Dabigatran EtexilateDabigatran Etexilate Mesylate70$16,777
Repatha SyringeEvolocumab24$15,266
Amiodarone Hcl135$7,190
Metoprolol Succinate437$6,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,134$567,844516 claims
Johnson & JohnsonXarelto$1,086$185,873183 claims
NovartisEntresto$1,135$146,285102 claims
E.r. Squibb & Sons, L.L.C.Camzyos$660$108,40414 claims
Boehringer IngelheimJardiance, Pradaxa$644$78,35269 claims
AstraZenecaFarxiga$797$69,60275 claims
Novo NordiskOzempic$51$33,64033 claims
MerckJanumet$753$6,14712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →